ASC as a marker for colorectal cancer
AssigneeRoche Diagnostics Operations, Inc.
InventorsHerbert Andres, Marie-Luise Hagmann, Johann Karl, Ursula Kunert, Gabriele Pestlin
Life of this patent
Estimating the term…
Abstract
The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein ASC (apoptosis-associated speck-like protein containing a caspase-associated recruitment domain) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring ASC in said sample. Measurement of ASC can, e.g., be used in the early detection or diagnosis of colorectal cancer.
Claims12
A method for assessing colorectal cancer in a patient comprising the steps of:
- measuring in a sample from the patient a concentration of apoptosis-associated speck-like protein containing a caspase-associated recruitment domain (ASC),
- correlating the concentration of ASC to the assessment of colorectal cancer.
A method for assessing colorectal cancer in a patient comprising the steps of:
- combining a sample from the patient with a specific binding agent for apoptosis-associated speck-like protein containing a caspase-associated recruitment domain (ASC) under conditions whereby a complex is formed between the binding agent and ASC, and
- correlating the amount of complex formed with the assessment of colorectal cancer.
A kit for assessing colorectal cancer in a patient, the kit comprising a specific binding agent for apoptosis-associated speck-like protein containing a caspase-associated recruitment domain (ASC) and a specific binding agent for a marker selected from the group consisting of neuron-specific enolase (NSE), soluble fragment of cytokeratin 19 (CYFRA 21-1), nicotinamide N-methyltransferase (NNMT), carbohydrate antigen 19-9 (CA 19-9), carbohydrate antigen 72-4 (CA 72-4), and carcinoembryonic antigen (CEA).
Dependencies are inferred from the claim text.